Microviable obtained two projects funded under CanSERV European call focused on “Reaching and Understanding of Cancer”
We are proud to announce that our research proposal “Exploring the relationships between anti-PD1 responders and gut microbiota: intervention with a highly purified microbiota as immunotherapy adjuvant” was selected for support by the EU-funded @canSERV project!
Two proposals submitted by Microviable were selected and funded to test our lead candidate MVT-201 in two different oncological targets:
- We are excited to work together with Fundaçao GIMM- Gulbenkian Institute for Molecular Medicine to carry out a preclinical model of CRC using MVT-201 as adjuvant for anti-PD1 immunotherapy.
- We are excited to work together with the Istituto Romagnolo per lo Studio dei Tumori “Dino Amatori” to perform a preclinical model of lung cancer using MVT-201 as adjuvant for anti-PD1 immunotherapy.
This service will help us move towards understanding how microbiome can overcome some barriers of immunotherapy and the key players involved in this phenomenon.
Support from canSERV enables cancer researchers to advance their research by providing access to a broad range of high-quality research services, accelerating impactful research across Europe.
We are very proud of our team and our R&Director David Ríos, PhD leading this area and proposals. Looking forward to fruitful projects and collaborations!
🔗 Learn more about canSERV: https://www.canserv.eu/
#CancerResearch #EUCancerMission #canSERV_EU”
